Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Mirati Therapeutics, Inc.
  6. Summary
    MRTX   US60468T1051

MIRATI THERAPEUTICS, INC.

(MRTX)
  Report
Real-time Estimate Cboe BZX  -  10:44:02 2023-02-02 am EST
54.82 USD   +4.03%
02/01Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
PR
01/23B. Riley Raises Mirati Therapeutics' Price Target to $56 From $52, Keeps Neutral Rating
MT
01/20Insider Sell: Mirati Therapeutics
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/27/2023 01/30/2023 01/31/2023 02/01/2023 02/02/2023 Date
53.09(c) 51.81(c) 53.41(c) 52.69(c) 54.335 Last
933 779 986 014 1 115 555 1 585 624 394 307 Volume
+3.98% -2.41% +3.09% -1.35% +3.12% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 14,3 M - -
Net income 2022 -752 M - -
Net cash position 2022 1 110 M - -
P/E ratio 2022 -3,93x
Yield 2022 -
Sales 2023 74,0 M - -
Net income 2023 -798 M - -
Net cash position 2023 423 M - -
P/E ratio 2023 -3,85x
Yield 2023 -
Capitalization 3 034 M 3 034 M -
EV / Sales 2022 134x
EV / Sales 2023 35,3x
Nbr of Employees -
Free-Float 94,1%
More Financials
Company
Mirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs:... 
Read more
More about the company
Ratings of Mirati Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MIRATI THERAPEUTICS, INC.
02/01Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
PR
01/23B. Riley Raises Mirati Therapeutics' Price Target to $56 From $52, Keeps Neutral Rating
MT
01/20Insider Sell: Mirati Therapeutics
MT
01/19Mirati Therapeutics Says FDA Clears Investigational New Drug Application For Tumor Ther..
MT
01/19Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Cla..
PR
01/19Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Invest..
CI
01/19Insider Sell: Mirati Therapeutics
MT
01/09Mirati Therapeutics, Inc. : Results of Operations and Financial Condition, Regulation FD D..
AQ
01/09Transcript : Mirati Therapeutics, Inc. Presents at 41st Annual J.P. Morgan He..
CI
01/06Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR
01/05Insider Sell: Mirati Therapeutics
MT
01/05U.S. new drug price exceeds $200,000 median in 2022
RE
2022Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
PR
2022Mirati Therapeutics Receives FDA Breakthrough Therapy Designation for Adagrasib-Cetuxim..
MT
2022Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation f..
PR
More news
News in other languages on MIRATI THERAPEUTICS, INC.
01/20Vente d'initiés : Mirati Therapeutics
01/19Mirati Therapeutics déclare que la FDA approuve la demande de nouveau médicament de rec..
01/19Mirati Therapeutics, Inc. annonce que la Food and Drug Administration des États-Unis au..
01/19Vente d'initiés : Mirati Therapeutics
01/05Vente d'initiés : Mirati Therapeutics
More news
Analyst Recommendations on MIRATI THERAPEUTICS, INC.
More recommendations
ETFs positioned on MIRATI THERAPEUTICS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
AGFiQ US Market Neutral Anti-Beta Fund - USD18.49%-3.18%United_States
ALPS Medical Breakthroughs ETF - USD2.28%1.04%United_States
Global X S&P Biotech ETF - AUD0.92%-1.19%-United_States
SPDR S&P Biotech ETF - USD0.92%0.09%United_States
Virtus LifeSci Biotech Clinical Trials ETF - USD0.83%2.38%United_States
More ETFs positioned on MIRATI THERAPEUTICS, INC.
Analysis
Amgen says Lumakras cuts risk of lung cancer progression by 34%
Chart MIRATI THERAPEUTICS, INC.
Duration : Period :
Mirati Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIRATI THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 52,69 $
Average target price 71,27 $
Spread / Average Target 35,3%
EPS Revisions
Managers and Directors
David D. Meek Chief Executive Officer & Director
Charles M. Baum President, Director & Head-Research & Development
Laurie D. Stelzer Chief Financial & Accounting Officer
Faheem Hasnain Chairman
James G. Christensen Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
MIRATI THERAPEUTICS, INC.16.29%3 034
VERTEX PHARMACEUTICALS11.88%81 440
REGENERON PHARMACEUTICALS, INC.5.06%80 956
WUXI APPTEC CO., LTD.15.90%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436